Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market for microbial-derived ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ...

Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated. As a ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...